Abstract. Pancreatic cancer (PCC) is one of the most dangerous types of tumor as it is very difficult to treat and its 5-year survival rate is <6%. To date, there have been no effective therapeutic strategies to treat PCC, thus, novel effective therapeutic methods are required. Tetraspanin 1 (Tspan1) is a novel member of the tetraspanins superfamily and is highly expressed in a variety of types of cancer, including gastric, hepatocellular and colonic carcinomas. However, the detailed functional role of Tspan1 in pancreatic cancer cells is still unclear and further investigation is required to uncover its therapeutic potential for the treatment of different tumor types. The purpose of the present study was to investigate the expression of Tspan1 in human PCC tissues and cells, and explore the effect of Tspan1 silencing on invasion, migration, cell survival and apoptosis in human PCC to clarify its function. Expression levels of Tspan1 were analyzed in human pancreatic cancer tissues and the cell lines Capan-2 and SW1990 using immunohistochemistry staining, reverse transcription-quantitative polymerase chain reaction and western blotting. The effects of downregulation of Tspan1 expression on cell survival, apoptosis, invasion and migration were investigated viaTspan1-small interfering (si)RNA transfection into human PCC cell lines. The results indicated that Tspan1 expression was increased in human PCC tissues compared with the adjacent normal pancreatic tissues. Tspan1 was highly expressed in the human PCC cell lines Capan-2 and SW1990 when compared with the normal pancreatic cell line HPC-Y5. In addition, transfection with siRNA-targeting Tspan1 significantly reduced cell migration and invasion, and increased the cell apoptosis of Capan-2 and SW1990. The present findings highlighted the important role of Tspan1 in human PCC cell migration, invasion and apoptosis. Thus, Tspan1 RNA interference may serve as a potential therapeutic strategy to treat human PCC.
Introduction
Pancreatic cancer (PCC) is currently one of the leading causes of cancer-associated mortality worldwide, with pancreatic ductal adenocarcinoma (PDAC) accounting for 80-90% of pancreatic tumor cases (1, 2) . The 5-year survival rate of PDAC patients is <6% and the average survival time of PDAC patients is <6 months (2) . The majority of patients are diagnosed in the advanced stages of cancer, and succumb due to cancer invasion and migration (3, 4) . In addition, the majority of patients with PDAC do not have long-term survival rates with the current therapeutic methods, which include surgical resection, radiation and chemotherapy (5) (6) (7) (8) . Therefore, the development of novel and effective therapeutic strategies is urgently required for the effective treatment of PDAC.
The tetraspanins heterogeneous superfamily (TM4SF) is composed of tetraspanin-enriched microdomains (TEMs). TM4SF has four transmembrane regions that interact with a number of cell surface signaling molecules, such as integrins (9, 10) . It has been reported that TEMs are involved in many fundamental biological processes, including cell proliferation, adhesion, proliferation, migration and signaling transduction (11, 12) . Tetraspanin 1 (Tspan1) is a novel member of the tetraspanins family, which is reported to be located at chromosome 1 p34.1 and encodes a protein with 241 amino acids (13) . Previous studies have demonstrated that Tspan1 is overexpressed in various tumor cells including cervical, lung, gastric, squamous cell and colon carcinomas, and liver and breast cancers (14) (15) (16) (17) (18) ; however, few studies have interpreted its role in PDAC. Xu et al (19) identified a differentially expressed Tspan1 gene in human prostate tissues and prostate cancer using cDNA database subtraction and microarray analysis. In addition, previous studies revealed that Tspan1 regulated human cancer progression in non-small cell lung and colon
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carcinomas, and skin squamous and cervical cancers (20) (21) (22) (23) (24) . However, the detailed functional role of Tspan1 in human PCC is still unclear.
In the present study, the expression of Tspan1 in human pancreatic cancer tissues, adjacent normal pancreatic tissues and human PDAC cell lines were detected using immunohistochemistry (IHC), reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blotting. Subsequently, following the transfection of Tspan1 small interfering (si)RNAs into human PCC cells, the expression of Tspan1 was analyzed by western blotting and RT-qPCR. Cell apoptosis and cell survival were detected by flow cytometry and an MTT assay. In addition, the effect of Tspan1 silencing on cell migration and invasion were explored using a Transwell assay. IHC. Anti-TSPAN1 antibody (1:200; cat no. NBP2-33867; Novus Biologicals, LLC, Littleton, CO, USA) was used for detecting TSPAN1expression with IHC staining. Tissue sections embedded in paraffin (4 µm) were sequentially deparaffinized and rehydrated, then antigens were retrieved at 95˚C using 10 mM citrate buffer (pH 6.0; Merck KGaA, Darmstadt, Germany). Freshly prepared 3% H 2 O 2 was used to quench the endogenous peroxidase activity. Normal serum (10%; Invitrogen; Thermo Fisher Scientific, Inc.) was used to block non-specific staining at room temperature for 1 h. Subsequently, sections were incubated with anti-TSPAN1 primary antibodies (1:500; cat.no. NBP2-33867; Novus Biologicals, LLC) at 37˚C for 2 h, which was followed by incubation with goat anti-rabbit IgG biotinylated antibodies (1:1,000; cat.no. BAF008; R&D Systems, Inc., Minneapolis, MN, USA) at room temperature for 30 min. Following this, sections were washed with PBS and then incubated with horseradish peroxidase-conjugated streptavidin (1:2,000; cat.no. N100; Thermo Fisher Scientific, Inc.) for 5 min at room temperature. 3,3-Diaminobenzidine substrate (Gene Tech Co., Ltd.) was used to develop the immunostaining for 10 min at room temperature. Finally, sections were counterstained with hematoxylin (Invitrogen; Thermo Fisher Scientific, Inc.) at room temperature for 3 min. Sections were incubated with PBS as negative control. The cells were examined under an inverted-TS100 microscope (Nikon Corporation, Tokyo, Japan). Furthermore, staining intensity was scored using the following criteria: ± (negative), + (weak), ++ (intermediate) and +++ (strong) (25) .
Materials and methods

Tissues
RT-qPCR. Briefly, RNA was extracted from tissues (100 mg) using 1 ml Trizol (Invitrogen Life Technologies), according to the manufacturer's instructions. Following this, tissues were homogenized and subsequently incubated at room temperature for 5 min. Following chloroform (Sigma-Aldrich; Merck KGaA) extraction and precipitation with isopropanol (Thermo Fisher Scientific, Inc.), the RNA pellet was washed with 75% ethanol (Sigma-Aldrich; Merck KGaA), air-dried and subsequently dissolved in nuclease-free water (30 µl; Ambion; Thermo Fisher Scientific, Inc.). RNA from cells was obtained using an RNeasy Mini kit (Qiagen GmbH, Hilden, Germany) following the manufacturer's protocol. Reverse transcription was performed as follows: A mixture of 2 µg total RNA and 1 µl Oligo (dT) was incubated at 70˚C for 5 min, rapidly chilled on ice and subsequently added to a reaction mixture containing 5 µl M-MLV RT 5X Buffer (Promega Corporation, Madison, WI, USA), 0.5 µl deoxyribonucleotide triphosphate (25 µM; Promega Corporation), 0.7 µl RNA inhibitors (Promega Corporation) and 1 µl M-MLV reverse transcriptase (200 U/µl; Promega Corporation). The reaction volume was made up to 25 µl with RNA-free water and subsequently incubated at 42˚C for 1 h and then 70˚C for 10 min. RT was performed on an Applied Biosystems 7900HT thermal cycler instrument (Applied Biosystems; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol (26) . Briefly, qPCR was carried out in a 20 µl reaction volume including 2XMix SYBR green I (10 µl; Promega Corporation), primer (0.25 µl, 10 pmol/l), template DNA (1 µl) and sterile water. The thermocycling conditions were as follows: Initial denaturation at 95˚C for 2 min, followed by 50 cycles of 95˚C for 15 sec and 60˚C for 45 sec. Fold change of target gene expression levels were calculated using the 2 -ΔΔCq method (27) . The following primer sequences were used: Human Tspan1 forward, 5'-CGT TGT GGT CTT TGC TCT TG-3' and reverse, 5'-TTC TTG ATG GCA GGC ACT AC-3'; Human GAPDH forward, 5'-GAA GGT GAA GGT CGG AGT C-3' and reverse, 5'-GAA GAT GGT GAT GGG ATT TC-3'. The relative Tspan1 mRNA expression level was normalized to the endogenous GAPDH mRNA expression.
Western blotting. Radioimmunoprecipitation Assay buffer (Sigma-Aldrich; Merck KGaA) as well as Protease Inhibitor (Sigma-Aldrich; Merck KGaA) were used to lyse cells (28) . Following protein collection, a BCA Pierce Assay (Thermo Fisher Scientific, Inc.) was used to quantify the protein concentration. Protein (50 µg) from each sample was denatured and resolved by 10% SDS-PAGE (EMD Millipore, Billerica, MA, USA) and electroblotted to a polyvinylidene fluoride (PVDF) membrane (EMD Millipore). PVDF membranes were incubated with 5% non-fat milk for one hour at room temperature and were then incubated with anti-TSPAN1 antibody (1:300; cat.no. NBP2-33867; Novus Biologicals, LLC, Littleton, CO, USA) or anti-β-actin antibody (1:1,000; cat.no. NB600-503; Novus Biologicals, LLC) at 4˚C overnight. Following washing with TBS with 5% Tween-20, the membrane was incubated with horseradish peroxidase-conjugated secondary antibodies (1:3,000; cat.no. NB710-57836; Novus Biologicals, LLC) for 1.5 h at room temperature. Finally, signals were developed by enhanced chemiluminescence (Pierce; Thermo Fisher Scientific, Inc.). The optical density of each protein band was quantified by a scanning densitometer and Quantity One software (version 4.4.1; Bio-Rad Laboratories, Inc., Hercules, CA, USA). Each lane of protein band density was normalized against corresponding β-actin densities.
Knockdown of Tspan1 in SW1990 and Capan-2 cells.
Expression of Tspan1 in SW1990 and Capan-2 cells was silenced using specific Tspan1 siRNAs [(Tspan1 siRNA-1 and siRNA-2 (assay IDs were S19659 and S19660, respectively; cat.no. 4392420; Thermo Fisher Scientific, Inc.)]. Scramble siRNA (siNC; cat.no. 4390846; Thermo Fisher Scientific, Inc.) was used to confirm the specificity of Tspan1 siRNAs. Non-transfected cells were used as a negative control. The Tspan1 siRNA-1 group sequences were 5'-GGC UCA CGA CCA AAA AGU Att-3' (sense) and 5'-UAC UUU UUG GUC GUG AGC Ctt-3' (antisense). The Tspan1 siRNA-2 group sequences were: 5'-GCU UUU GUA UGA CAU CCG Att-3' (sense), 5'-UCG GAU GUC AUA CAA AAG Ctg-3' (antisense). The scramble siRNA group sequences were 5'-UUC UCC GAA CGU GUC ACG UdT dT-3' (sense), 5'-ACG UGA CAC GUU CGG AGA AdT dT-3' (antisense). The siRNAs transfection into Capan-2 and SW1990 cells was performed following the manufacturer's protocol. Briefly, a total of 1x10 5 cells/ml of SW1990 and Capan-2 cells were re-suspended in DMEM medium. Transfection complexes were prepared by mixing RNAiMAX Lipofectamine transfection agent (Ambion; Thermo Fisher Scientific, Inc.) and Tspan1 siRNA (20 nM) or scramble siRNA (20 nM) in DMEM medium. SW1990 and Capan-2 cells, and the transfection complexes were mixed and incubated for 24 h at 37˚C in 6-well (2x10 5 cells/well) plates (NalgeNunc International, Penfield, NY, USA). Cells were collected at 48 h post-transfection for RNA analysis and 72 h for protein analysis. The knockdown of Tspan1 was confirmed by RT-qPCR and western blot analysis.
In vitro cell migration and invasion assay. The cell migration was detected using the BD Falcon HTS multi-well insert system (pore size, 8.0 µm) (29) . A total of 1.5x10 5 SW1990 and Capan-2 cells, or transfected SW1990 and Capan-2 cells in serum-free DMEM were plated in the upper chamber of the insert; in the bottom wells 500 µl DMEM containing 10% FCS was plated. Following incubation for 6 h at 37˚C, cotton swabs were used to carefully scrape off the non-migrated cells (the cells remaining in the insert). The migrated cells (the cells at the bottom of the insert) were fixed with 4% formaldehyde for 20 min at room temperature, and then stained with 0.1% crystal violet for 30 min at room temperature. Milli-Q water was used to wash away the excess stain and the filters were dried overnight. Migrated cells were manually counted in five random fields and images were obtained using light microscopy and camera (Nikon Digital Camera Dxm 1200F; Nikon Corporation).
The cell invasion assay was performed using the BioCoat Matrigel invasion chambers (BD Biosciences, Franklin Lakes, NJ, USA) (30) . Reduced serum Matrigel (50 µg; BD Biosciences) was added to coat Transwell inserts. Following transfection, a total of 1x10 6 SW1990 and Capan-2 cells in serum-free DMEM were plated in the upper chamber. DMEM with 10% FCS was plated in the lower chamber as the chemoattractant. Following 48 h of incubation at 37˚C, the membrane containing the invaded cells was taken off gently and mounted on a glass slide, then the slide was fixed with 4% formaldehyde for 20 min at room temperature and stained with 0.1% crystal violet at room temperature for 30 min. Invaded cells were counted in five random fields and images obtained using light microscopy and camera (Nikon Digital Camera Dxm 1200F; Nikon Corporation). 
Cell survival (MTT) assay.
To investigate the effect of Tspan1 downregulation on the proliferation and viability of SW1990 and Capan-2 cells, MTT assays were performed at 0, 24, 48, 72, 96 and 120 h time intervals following transfection. A total of 3x10 4 cells were seeded into 96-well plates a day prior to transfection. Cells were cultured in a 5% CO 2 incubator at 37˚C for 4 h with 150 µl DMEM containing 20 µl MTT (5 mg/ml; Sigma-Aldrich; Merck KGaA) per well. Following incubation, the medium was then gently aspirated and 150 µl of dimethyl sulfoxide (Sigma-Aldrich; Merck KGaA) was subsequently added to each well to solubilize the formazan crystals. The absorbance of formazan was determined at a wavelength of 570 nm and a reference wavelength of 630 nm using a Bio-Rad Microplate Reader 550 (Bio-Rad Laboratories Inc.). Cell growth curves were subsequently plotted using the mean ± standard deviation data.
Statistical analysis.
The results were expressed as the mean ± standard deviation of at least three independent experiments performed in triplicate. The difference between two groups was analyzed using the two-tailed Student's t-test and SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA). One-way analysis of variance followed by the Tukey's post hoc test were used to assess significant differences among groups by SPSS 17.0 software (SPSS, Inc.). P<0.05 was considered to indicate a statistically significant difference.
Results
Expression of Tspan1 in human PCC tissues and cells.
IHC was used to detect the expression status of TSPAN1 in human carcinoma and adjacent normal pancreatic tissues. The results indicated that there were greater levels of TSPAN1 protein in PCC tissues (Fig. 1A, right) than there were in the adjacent normal pancreatic tissues (Fig. 1A, left) . Positive TSPAN1 immunostaining was mainly localized in the cytoplasm of carcinoma tissue cells. The statistical analysis results of TSPAN1 expression in human pancreatic tumor tissues and adjacent normal pancreas tissues are presented in Fig. 2 . The mRNA expression levels of Tspan1 were measured in the PDAC cell lines Capan-2 and SW1990, and the normal pancreatic cell line HPC-Y5 using RT-qPCR. The results demonstrated that the SW1990 and Capan-2 cells expressed higher levels of Tspan1 mRNA when compared with the normal pancreatic cell line HPC-Y5 (Fig. 1B) . TSPAN1 protein expression was also detected using western blotting. The results revealed that the SW1990 and Capan-2 cells expressed higher levels of TSPAN1 protein compared with the normal pancreatic cell line HPC-Y5 (Fig. 1C) .
Knocking down Tspan1 expression by siRNA transfection.
The human PDAC cell lines SW1990 and Capan-2 were transfected with Tspan1-siRNAor siNC, which was used to confirm the specificity of Tspan1 siRNAs. Tspan1 mRNA and protein expression levels were determined using RT-qPCR and western blotting, respectively, to confirm that its expression was silenced. The results revealed that there were no differences in Tspan1 expression levels between siNC cells and untransfected control cells (Fig. 3) . RT-qPCR results demonstrated that Tspan1 mRNA expression was significantly knocked down in the Tspan1-siRNAs transfected cells compared with control cells that had not been transfected with siRNA (Fig. 3A) . Western blotting results demonstrated that the protein levels of TSPAN1 were significantly lower in Tspan1-siRNAtransfected cells when compared with the control cells (Fig. 3B and C) .
Knockdown of Tspan1 inhibits SW1990 and Capan-2 cell migration and invasion. FollowingTspan1-siRNAs transfection, the migration ability of Tspan1 knockdown cells, control cells and non-targeted siNC-transfected cells was determined and analyzed. The results demonstrated that in the Tspan1-siRNA1 and Tspan1-siRNA2 transfected groups the migrated cells were significantly decreased when compared with that of the control (Fig. 4A) . Subsequently, the invasion ability of Capan-2 and SW1990 cells following the knockdown of Tspan1 was determined using the Transwell invasion method. The results indicated that Tspan1-siRNA transfection significantly suppressed cell invasion (Fig. 4B) . No significant differences in migration and invasion abilities between siNC cells and control cells were observed. Taken together, the results indicated that knockdown of Tspan1 inhibited cell migration and invasion.
Effects of Tspan1 knockdown on cell survival and apoptosis.
The effects of Tspan1 knockdown on cell survival and cell apoptosis were determined. The results of the MTT assay indicated that knockdown of Tspan1 did not exhibit a marked effect on cell survival (Fig. 5A) . The results of flow cytometric analysis indicated that the percentage of apoptotic cells was increased in the Tspan1-siRNA transfection SW1990 groups, when compared the levels observed in the control groups (60.16±3.33 and 70.15±9.97% vs. 9.12±1.13 and 8.37±1.24%; Figs. 5B and 6 ). The percentage of apoptotic cells was also increased in the Tspan1-siRNA transfection Capan-2 groups (data not shown).
Discussion
Despite the number of treatments available for patients with PCC including, surgery resection, radiation, chemotherapy and a combination of these modalities, PCC still has the worst prognosis among all of the other major tumors; following diagnosis, the 5 years survival rate is <6% (1,4) . Therefore, novel therapeutic strategies are urgently required.
It has been reported that tetraspanins, the transmembrane protein family, may be involved in the regulation of cell survival, growth, proliferation, differentiation, motility, and cancer cell migration and invasion (9, 11) . In a number of human tumors, it has been demonstrated that the expression of tetraspanins was increased, which was associated with cancer progression (12) . Tspan1 is a novel member of the tetraspanins family. Previous studies revealed that the expression of Tspan1 was increased or overexpressed in a variety of human carcinomas (14) (15) (16) (17) (18) . The present study also demonstrated that the expression of TSPAN1 in human PCC was significantly higher than that observed in the adjacent normal pancreatic tissues. Therefore, these results may indicate that TSPAN1 expression could be used as a specific marker for human PCC in future strategies for diagnosis and treatment; however, further investigation is required to explore this hypothesis.
Previous studies have revealed that Tspan1 is involved in processes associated with tumor progression, including cell survival, proliferation, migration and invasion (14-18). Chen et al (22, 23) indicated that the knockdown of Tspan1 suppressed human colon cancer and skin carcinoma cell survival, proliferation, migration and invasion. Hölters et al (31) revealed that TSPAN1 promoted human cervical tumor cell migration and invasion. These studies implied that Tspan1 may serve an important role in cancer progression, while the detailed function of Tspan1 in human pancreatic tumor cells is still unclear. In the present study, the role of Tspan1 was explored in human PCC cells. The results indicated that the expression of Tspan1 was increased in human PCC tissues and the human PDAC cell lines Capan-2 and SW1990. Tspan1 expression was silenced following transfection with Tspan1 siRNA1 and siRNA2 into SW1990 and Capan-2 cells. The present findings indicated that silencing Tspan1 expression suppressed human pancreatic tumor cell migration and invasion, and induced the cell apoptosis of SW1990 and Capan-2 cells, which was consistent with previous findings in different tumor cells (20, 22, 32) . These findings indicated that Tspan1 may act as an oncogene. However, the MTT assay results indicated that knockdown of Tspan1 had no effect on cell viability and proliferation. It is possible that the remaining viable cells exhibited exceptionally high metabolic activity, therefore converting a comparable amount of MTT assay substrate as non-knockdown cells. In addition, it is also possible that the number of remaining live cells was too large, and the MTT was oversaturated. In future studies, the group will repeat these experiments and explore the underlying mechanisms.
Previous studies have demonstrated that Tspan1 and integrin α6 expression act as potential biomarkers in gastric, colonic, hepatic and esophageal carcinomas (33, 34) ; however, conflicting findings regarding their prognostic role have been reported in PDAC (35) . The results of the present study demonstrated that Tspan1 was mainly expressed in the cytoplasm of human PCC cells. When Tspan1 is located on the cell membrane it may interact with extracellular signals and carry out functions in the cytoplasm, which is similar to other Tetraspanins including CD63, CD82 and CD9 (29, 33, 36) . Thus future studies, including microarray analysis to investigate cancer associated genes regulated by Tspan1, and the underlying mechanism, are required.
In conclusion, the results of the present study indicated that Tspan1 expression was increased in human pancreatic tumor tissues and cell lines. The function of Tspan1 in human PCC progression was also investigated using Tspan1 siRNA. The results indicated that following the transfection of Capan-2 and SW1990 cells with Tspan1 siRNAs, cell migration and invasion were suppressed, and cell apoptosis was induced. These findings highlighted the important functional role of Tspan1 in human PCC progression. The results of the present study indicated that Tspan1 may be effective as a biomarker for PCC; however, further investigation is required to explore this hypothesis. siRNA targeting of Tspan1 may be a potential therapeutic strategy for the treatment of Tspan1 expressing pancreatic and other cancers, though further studies are required in the future.
